e-learning
resources
Virtual 2021
07.09.2021
Paediatric respiratory infections: chronic infection, vaccination and lung function
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.
M. Elashmawy (Cambridge (Cambridgeshire), United Kingdom), J. Baker (Cambridge (Cambridgeshire), United Kingdom), T. Polychronakis (Cambridge (Cambridgeshire), United Kingdom)
Source:
Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Session:
Paediatric respiratory infections: chronic infection, vaccination and lung function
Session type:
E-poster
Number:
3150
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Elashmawy (Cambridge (Cambridgeshire), United Kingdom), J. Baker (Cambridge (Cambridgeshire), United Kingdom), T. Polychronakis (Cambridge (Cambridgeshire), United Kingdom). Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.. 3150
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Year: 2015
Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13)
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure
Source: Eur Respir J 2006; 28: Suppl. 50, 576s
Year: 2006
The remaining challenges of pneumococcal disease in adults
Source: Eur Respir Rev 2012; 21: 57-65
Year: 2012
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Source: Eur Respir J 2002; 20: 813-818
Year: 2002
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV)
Source: Eur Respir J 2005; 26: Suppl. 49, 286s
Year: 2005
Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Eur Respir Rev 2008; 17: 43-45
Year: 2008
Perception and uptake of the influenza and pneumococcal vaccinations in patients with COPD
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Efficacy of influenza and pneumococcal vaccinations among patients with COPD
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept